- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02512926
Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children (POE14-01)
Phase I Study of Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children With Relapsed and Refractory Solid Tumors and Leukemias
This study evaluates the use of carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed/refractory solid tumors or leukemia. The medications cyclophosphamide and etoposide are standard drugs often used together for the treatment of cancer in children with solid tumors or leukemia.
Carfilzomib is FDA (Food and Drug Administration) approved in the United States for adults with multiple myeloma (a type of cancer). However, this drug is not approved to treat children with relapsed/refractory solid tumors or leukemia. With this research, we plan to determine the DLTs and MTD of Carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors.
Study Overview
Status
Intervention / Treatment
Detailed Description
Part 1 of the study will include a dose escalation based on Dose limiting toxicities (DLTs) until the MTD or highest dose level is reached, whichever comes first.
At the MTD or highest dose level (if no MTD is reached), an additional 6 patients will be enrolled to further evaluate safety of the regimen (Part 2).
Part 2 of this study will enroll additional patients at the highest tolerable dose found in Part 1 in order to get more information on side effects and make sure the dose is tolerable
Once an MTD is determined for Strata A or B, if the Study Principal Investigator determines that the study treatment should not be further pursued due to safety or enrollment barriers, the expansion Part or the study will be discontinued.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Norman Lacayo, MD
- Phone Number: 650-723-5533
- Email: lacayon@stanford.edu
Study Contact Backup
- Name: Aru Narendran, MD, PhD
- Phone Number: 403-210-6418
- Email: anarendr@ucalgary.ca
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T3B 6A8
- Alberta Children's Hospital
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85016
- Phoenix Children's Hospital
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72202
- Arkansas Children's Hospital
-
-
California
-
Palo Alto, California, United States, 94304
- Stanford University School of Medicine and Stanford Cancer Institute
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Dana Farber Cancer Institute
-
-
New York
-
New York, New York, United States, 10065
- Memorial Sloan-Kettering Cancer Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, United States, 17033-0850
- Penn State Hershey Children's Hospital
-
-
Texas
-
San Antonio, Texas, United States, 78229
- University of Texas Health Science Center at San Antonio
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients must have either of the following:
Relapsed/refractory leukemia in 2nd or greater relapse or who have failed at least one re-induction attempt after relapse or for refractory disease. Patients must meet the WHO classification with ≥ 5% blasts in the bone marrow or must have definitive extramedullary disease (e.g. chloromas, skin lesions). Patients may have asymptomatic CNS 1 or CNS 2 disease, but not CNS 3 or symptomatic CNS disease.
OR
- Relapsed/refractory non-CNS solid tumor that has not responded or has relapsed and for which no standard treatment is available. Patients may not have primary CNS tumors or CNS metastases. Lymphoma patients are permitted. Patients do not need to have measurable disease.
- Age 6 months - 29.99 years at enrollment
- Life expectancy ≥ 3 months
- Lansky or Karnofsky ≥50
Prior therapy
- Patient must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, radiotherapy, or surgery prior to study entry.
- Myelosuppressive therapy- At least 14 days must have elapsed since the administration of previous therapy. Six weeks must have elapsed from the administration of nitrosureas or mitomycin C. For patients with ALL on maintenance therapy, they may be eligible if 7 days have elapsed and they are recovered from the toxic effects of the chemotherapy. This restriction does not include intrathecal chemotherapy, which is permitted.
- Biologic agents- At least 14 days must have elapsed since the completion of therapy with a biologic agent such as a monoclonal antibody. Seven days must have elapsed since the last dose of retinoids
- Radiation therapy - At least 14 days must have elapsed for local XRT. At least 90 days must have elapsed if prior radiation to ≥50% of the pelvis, the spine, or other substantial bone marrow radiation including TBI.
- Hematopoietic growth factors- At least 7 days must have elapsed since the last dose of G-CSF or GM-CSF. At least 14 days must have elapsed since last dose of pegfilgrastim (Neulasta®).
- Patient must be ≥ 3 months from hematopoietic stem cell transplant, must not have active GVHD, and must be off all immunosuppression
Organ function:
- Either a serum creatinine ≤ ULN for age, or calculated or measured GFR ≥ 70 mL/min/1.73 m2
- Total bilirubin ≤ 1.5 x ULN for age, direct bilirubin ≤ ULN for age
- AST and ALT ≤ 3 x ULN for age unless elevation can be clearly attributed to liver leukemia or metastases
- ECHO shortening fraction ≥ 27%
- Pulse Oximetry measurement ≥ 95% saturation without supplemental oxygen
Bone marrow function:
- Hgb ≥10 g/dL - can be transfused
- Plts ≥ 75,000 - cannot be transfused (must be ≥ 7 days from last plt transfusion)
- ANC ≥ 750 - cannot be transfused (must be ≥ 72 hours from last neutrophil infusion)
However, the plt and ANC requirements can be waived if low counts thought to be secondary to leukemia or tumor bone marrow infiltration
Reproductive function:
- Female patients of childbearing potential must have a negative serum pregnancy test confirmed within 7 days prior to enrollment
- Female patients with infants must agree not to breastfeed their infants while on the study
- Male and female patients of child-bearing potential must agree to use an effective method of contraception approved by the investigator during the study and for a minimum of 3 months after study treatment
- Written informed consent
Exclusion Criteria:
- Prior treatment with carfilzomib
- Known allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).
- Down syndrome
- Fanconi Anemia or other underlying bone marrow failure syndrome
- Pregnant or lactating females
- Known history of Hepatitis B or C or HIV
- Patient with any significant concurrent illness
- Patient with uncontrolled systemic fungal, bacterial, viral or other infection with ongoing signs/symptoms despite appropriate treatment
- Patient with illness, psychiatric disorder or social issue that could compromise patient safety or compliance with the protocol treatment or procedures, or interfere with the consent, study participation, follow-up, or interpretation of study results.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Carfilzomib
Carfilzomib in combination with cyclophosphamide and etoposide
|
Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the DLTs and MTD of carfilzomib given in combination with cyclophosphamide and etoposide in pediatric patients with relapsed/refractory leukemias and solid tumors
Time Frame: 30 Days post treatment initiation
|
30 Days post treatment initiation
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To evaluate toxicities of carfilzomib in the pediatric population when combined with conventional chemotherapy.
Time Frame: Treatment initiation through 30 days post treatment
|
Record AEs and SAEs
|
Treatment initiation through 30 days post treatment
|
Determine patient response rate (CR, PR, SD, PD) with this regimen
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To measure if circulating plasma proteosome (cProt) levels post treatment correlate with response to therapy and overall survival.
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To measure if the levels of proteasome activity and resistance to carfilzomib correlates with toxicity and/or response to treatment
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To measure if inhibition of proteasome activity by carfilzomib results in alteration in a number of autophagy and apoptosis related proteins, providing means to evaluate correlates of activity of carfilzomib
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To measure the level of proteosome inhibition in patient PBMCs before and during treatment by determination of the level of protein ubiquitination
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To determine in vitro sensitivity of patient leukemias and solid tumors to carfilzomib alone and in combination with study chemotherapeutic agents in order to generate a predictive model of drug sensitivity
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
|
To perform whole exome sequencing (WES) and RNA seq on patient leukemia and solid tumor samples and WES on germ line DNA in order to determine potential mechanisms of drug sensitivity or resistance
Time Frame: Treatment initiation through 30 days post treatment
|
Treatment initiation through 30 days post treatment
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Neoplasms by Histologic Type
- Neoplasms
- Leukemia
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antirheumatic Agents
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Myeloablative Agonists
- Antineoplastic Agents, Phytogenic
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Cyclophosphamide
- Etoposide
Other Study ID Numbers
- IRB-37313
- PEDSVAR0042 (Other Identifier: Stanford - OnCore)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Refractory Leukemia
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Acute Myeloid Leukemia | Recurrent Chronic Myelomonocytic Leukemia | Recurrent Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Refractory Chronic Myelomonocytic Leukemia | Refractory Myelodysplastic Syndrome | Refractory Mixed Phenotype Acute Leukemia | Refractory Acute Leukemia... and other conditionsUnited States
-
Sumithira VasuRecruitingRecurrent B Acute Lymphoblastic Leukemia | Refractory B Acute Lymphoblastic Leukemia | Refractory Chronic Lymphocytic Leukemia | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Recurrent High Grade... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Previously Treated Myelodysplastic Syndromes | Refractory Anemia With Excess Blasts | Refractory Anemia With Excess Blasts in TransformationUnited States
-
Skyline Diagnostics BVIllumina, Inc.TerminatedAcute Myeloid Leukemia (AML) | Acute Promyelocytic Leukemia (APL) | Refractory Anemia With Excess of Blasts (RAEB)United States, Germany, Netherlands, United Kingdom
-
Case Comprehensive Cancer CenterCompletedMyelodysplastic Syndromes | Thrombocytopenia | Chronic Myelomonocytic Leukemia | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Ringed SideroblastsUnited States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Previously Treated Myelodysplastic Syndromes | de Novo Myelodysplastic Syndromes | Refractory Anemia | Refractory Anemia With Excess Blasts | Refractory Cytopenia With Multilineage Dysplasia | Refractory Anemia With Excess Blasts in Transformation | Refractory Anemia...United States
-
National Cancer Institute (NCI)CompletedChronic Myelomonocytic Leukemia | Childhood Acute Erythroleukemia (M6) | Childhood Acute Megakaryocytic Leukemia (M7) | Childhood Acute Monoblastic Leukemia (M5a) | Childhood Acute Monocytic Leukemia (M5b) | Childhood Acute Myeloblastic Leukemia With Maturation (M2) | Childhood Acute Myeloblastic... and other conditionsUnited States
-
Hannover Medical SchoolUniversity Hospital, Ghent; Johann Wolfgang Goethe University Hospital; University... and other collaboratorsUnknownDe Novo Akute Myeloid Leukemia (AML) | Secondary Acute Myeloid Leukemia (AML) | Refractory Anemia With Excess of Blasts in TransformationGermany
-
LLS PedAL Initiative, LLCKura OncologyNot yet recruitingRelapsed/Refractory KMT2A-r Acute Leukemia | Relapsed/Refractory NUP98-r Acute Leukemia | Relapsed/Refractory NPM1-m Acute Leukemia
-
Dana-Farber Cancer InstituteNational Institutes of Health (NIH); Brigham and Women's HospitalCompletedAcute Myeloid Leukemia | Chronic Myelomonocytic Leukemia | Myelodysplastic Syndrome-Refractory Anemia With Excess BlastsUnited States
Clinical Trials on Cyclophosphamide
-
Children's Hospital Los AngelesLucile Packard Children's HospitalTerminatedMetabolic Diseases | Stem Cell Transplantation | Chronic Granulomatous Disease | Bone Marrow Transplantation | Thalassemia | Wiskott-Aldrich Syndrome | Genetic Diseases | Peripheral Blood Stem Cell Transplantation | Pediatrics | Diamond-Blackfan Anemia | Allogeneic Transplantation | Combined Immune Deficiency | X-linked Lymphoproliferative Disease
-
Medical College of WisconsinNational Cancer Institute (NCI); National Heart, Lung, and Blood Institute... and other collaboratorsCompletedAnemia, AplasticUnited States
-
Columbia UniversityUnknownSevere Combined Immunodeficiency | Fanconi Anemia | Bone Marrow Failure | OsteopetrosisUnited States
-
National Cancer Institute, NaplesImmatics Biotechnologies GmbH; CureVac; European Commission -FP7-Health-2013-Innovation-1CompletedHepatocellular CarcinomaBelgium, Germany, Italy, Spain, United Kingdom
-
Mahidol UniversityTerminatedRenal Insufficiency | InfectionThailand
-
Eisai Inc.CompletedBreast Cancer | Ovarian Cancer | Prostate Cancer | Colon Cancer | Renal CancerUnited States
-
Centre Oscar LambretCompleted
-
Baylor Research InstituteCompletedMalignant Melanoma Stage IVUnited States
-
University of Turin, ItalyUnknown
-
Merck KGaA, Darmstadt, GermanyCompleted